40 completed, 8 terminated, 4 recruiting, 4 withdrawn. 63 Phase 1, 26 Phase 2.
Follow Hypoglycemia: new trials by email Literature Review of Hypoglycemia trials Research Report on Hypoglycemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Safety and Efficacy of Pancreatic Endocrine Cells in Adult Patients With Type 1 Diabetes Allogeneic pancreatic endocrine cell clusters - Diabete Mellitus, Diabete Type 1 | Phase 1 / Phase 2 | Not yet recruiting | Seraxis | 9 | 2026-11-01 | 2026-10-19 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes PAL-119, Placebo - Healthy Volunteers and Diabetes Participants | Phase 1 / Phase 2 | Not yet recruiting | Paulex Bio Inc. | 147 | 2026-11-01 | 2026-10-28 |
| A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes Allogeneic Human E-islet (E-islet 01) - Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness | Phase 1 / Phase 2 | Recruiting | EndoCell Therapeutics, Inc. | 21 | 2025-08-11 | 2025-08-22 |
| A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus OPF-310 - Diabetes Mellitus, Type 1, Hypoglycemia | Phase 1 / Phase 2 | Recruiting | Otsuka Pharmaceutical Factory, Inc. | 13 | 2025-06-10 | 2026-08-21 |
| A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 Diabetes Patients With Severe Hypoglycemia Allogeneic Pancreatic Endocrine Cell Clusters - Diabetes Mellitus Type 1 | Phase 1 / Phase 2 | Withdrawn | Seraxis | 2025-04-01 | 2025-10-16 | |
| Diabetes Islet Preservation Immune Treatment Anti-Thymocyte Globulin (ATG), Interleukin 2, Exenatide - Diabetes Mellitus, Type 1, Hypoglycemia | Phase 1 / Phase 2 | Withdrawn | Camillo Ricordi and Jay Skyler | 2024-06-01 | 2026-01-15 | |
| Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D AT-1501 IV Infusion, Isolated cadaveric islet cells - Brittle Type 1 Diabetes Mellitus | Phase 1 / Phase 2 | Withdrawn | Eledon Pharmaceuticals | 2022-09-30 | 2023-01-18 | |
| ENSO 16 - Study in Healthy Subjects ENSO 16, Glucose Powder - Sugar; Blood, Low | Phase 1 | Completed | Alpha Republic GmbH | 15 | 2022-04-28 | 2023-02-21 |
| A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes Glucagon Nasal Powder [Baqsimi] - Type 1 Diabetes | Phase 1 | Completed | Eli Lilly and Company | 7 | 2022-03-24 | 2024-05-23 |
| A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Lyumjev with 50% basal rate reduction, Humalog with 50% basal rate reduction, Humalog with 100% basal rate reduction - Diabetes Mellitus, Type 1 | Phase 1 | Completed | Eli Lilly and Company | 25 | 2022-02-14 | 2024-09-03 |
| Effect of ZT-01 on Glucagon During Hypoglycemia in Type 1 Diabetes Mellitus ZT-01 low dose, ZT-01 high dose, Placebo - Type 1 Diabetes, Hypoglycemia | Phase 1 | Terminated | Zucara Therapeutics Inc. | 24 | 2021-07-08 | 2023-07-12 |
| EFFECTS OF MOXIFLOXACIN AND GEMIFLOXACIN ON BLOOD GLUCOSE AND ECG MORPHOLOGY OF EUGLYCEMICS:A CLINICAL STUDY Moxifloxacin 400mg, Gemifloxacin 320 MG - Blood Glucose, Low, Hypoglycemia | Phase 1 | Completed | Shaheed Benazir Bhutto University Sheringal Dir Upper | 25 | 2021-03-01 | 2023-04-12 |
| A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus Tirzepatide, Placebo - Diabetes Mellitus, Type 2, Hypoglycemia | Phase 1 | Completed | Eli Lilly and Company | 42 | 2020-02-24 | 2024-05-20 |
| Insulin Tolerance Test Study in Patients With Type 1 Diabetes Pitolisant - Type 1 Diabetes, Hypoglycemia | Phase 1 | Terminated | High Point Clinical Trials Center | 5 | 2019-09-15 | 2021-04-02 |
| Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus glucokinase activator, Placebo - Type2 Diabetes Mellitus | Phase 1 | Completed | PegBio Co., Ltd. | 16 | 2019-08-27 | 2020-01-22 |
| Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes Allogenic Human Islet Cells, Gastrin 17 - Diabetes Mellitus, Type 1 | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 20 | 2019-05-29 | 2026-10-15 |
| A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation Sernova Cell Pouch - Type 1 Diabetes Mellitus | Phase 1 / Phase 2 | Active not recruiting | Sernova Biotherapeutics Inc. | 17 | 2019-02-07 | 2026-02-25 |
| Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration Dasiglucagon, Placebo - Hypoglycemia | Phase 1 | Completed | Zealand Pharma | 60 | 2018-11-07 | 2021-03-23 |
| Liver Glycogen and Hypoglycemia in Humans Low Fructose, Saline, Somatostatin - Hypoglycemia; Iatrogenic | Phase 1 | Active not recruiting | Jason Winnick | 40 | 2018-08-02 | 2025-07-25 |
| Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients Cholecalciferol, Omega 3 fatty acid - Diabetes Mellitus, Type 1, Hypoglycemia | Phase 1 / Phase 2 | Completed | Rodolfo Alejandro | 27 | 2018-07-23 | 2025-09-17 |
Showing 20 of 63. Sign in to see all of them.
Diabetes Mellitus, Type 1 (30) · Diabetes Mellitus (17) · Hyperglycemia (10) · Congenital Hyperinsulinism (7) · Autoimmune Diseases (4) · Hyperinsulinism (4) · Diabetes Mellitus, Type 2 (3) · Glucose Metabolism Disorders (3) · Metabolic Diseases (3) · Endocrine System Diseases (2) · Immune System Diseases (2) · Insulin Resistance (2) · Burns (1) · Diabetic Ketoacidosis (1)
Nutritional and Metabolic Diseases (63) · Glucose Metabolism Disorders (60) · Metabolic Diseases (60) · Endocrine System Diseases (37) · Immune System Diseases (29) · Autoimmune Diseases (26) · Diabetes Mellitus (20) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Digestive System Diseases (7) · Infant, Newborn, Diseases (6) · Pancreatic Diseases (6) · Hyperinsulinism (5) · Neoplasms (2) · Pathological Conditions, Signs and Symptoms (2)
Glucagon (5) · Insulin (5) · exendin (9-39) (5) · Glucagon-Like Peptide 1 (4) · Islets of Langerhans Transplantation (4) · Antilymphocyte Serum (3) · Exenatide (3) · Saline Solution (3) · Sodium Chloride (2) · thymoglobulin (2) · 3-Hydroxybutyric Acid (1) · AZD1656 (1) · Acarbose (1) · Acetylcysteine (1) · Adalimumab (1)
University of Minnesota (9) · Eli Lilly and Company (4) · Baylor Research Institute (3) · Diva De Leon (3) · Zealand Pharma (3) · Bows Pharmaceuticals AG (2) · Rodolfo Alejandro (2) · Seraxis (2) · Tracey McLaughlin (2) · Yale University (2) · Alpha Republic GmbH (1) · AstraZeneca (1) · Bayhill Therapeutics (1) · Biodel (1) · Camillo Ricordi and Jay Skyler (1)
United States (40) · Germany (5) · Australia (2) · Austria (2) · Canada (2) · China (2) · Sweden (2) · France (1) · Netherlands (1) · New Zealand (1) · Pakistan (1) · Switzerland (1) · United Kingdom (1)
Bernhard J. Hering, M.D. (5) · Nabil Al-Tawil, M.D.; Ph.D. (2) · Abid Ullah, Ph.D Scholar (1) · Alan Krasner, MD (1) · Alfred Penfornis, MD, PhD (1) · Amir Moheet, MD (1) · Benjamin A. Kohl, MD (1) · Camillo Ricordi, M.D. (1) · Charles Thivolet, MD, PhD (1) · Christina M Sylvest, MSc Pharm (1) · Colleen Craig, M.D. (1) · Cyrille Colin, MD, PhD (1) · Devi S Nambudripad, DC,L.Ac,PhD (1) · Diva D De Leon, MD (1)
PMID 14961992, PMID 15713772, PMID 22855730, PMID 26068866, PMID 26345338, PMID 27975209, PMID 32514794, PMID 32661108, PMID 34282646, PMID 34805810, PMID 35203750, PMID 35416981, PMID 35464292, PMID 38444629, PMID 38914694, PMID 39780302, PMID 40964167, PMID 42168649
2017 (1), 2019 (1), R01DK062440 (1), R01DK101984 (1), R03DK078535 (1)